Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to support margin expansion, profitability, and cash flow. Deepens vertical integration: expected to drive synergies, optimized production, economies of scale, expanded capacity, and a strengthened R&D engine. State-of-the-art production plant: GMP-licensed, approximately 59,000 square feet, built to the highest European standards, providing a clear growth avenue. Manufacturing excellence: a broad range of dosage forms, certified to GMP, ISO, Kosher, and Halal standards, with site registrations for the UAE, Qatar, Iraq and Lebanon. Boosts product portfolio: adds advanced and branded generics and OTC pharmaceutical products to the Cosmos Health portfolio. CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered into a non-binding letter of intent (the "LOI") to acquire 100% of Doc Pharma S.A. ("Doc Pharma"), a fully licensed GMP pharmaceutical manufacturer. The proposed acquisition would mark a defining step in Cosmos Health's strategy to build a fully integrated, end-to-end healthcare platform. Doc Pharma operates an approximately 59,000-square-foot, GMP-licensed production facility built to the highest European standards, with room to expand. Its capabilities include: Broad dosage-form range: tablets, hard capsules, sachets, syrups, suspensions, solutions, drops, and sprays, supporting a wide variety of pharmaceutical and nutraceutical products. Comprehensive certifications: GMP, ISO, Kosher, and Halal, with site registrations for the UAE, Qatar, Iraq and Lebanon. Rigorous quality control: independent chemical and microbiological laboratories operating to GLP guidelines, with testing aligned to European, British, and US Pharmacopeia monographs. The proposed acquisition is expected to deliver significant strategic benefits, including: Deeper vertical integration, capturing value across the entire value chain. Economies of scale and improved margins through consolidated, higher-utilization production. Expanded capacity and additional production lines, broadening the dosage forms Cosmos Health can manufacture in-house. An enlarged product portfolio of advanced and branded generics and OTC pharmaceutical products. A strengthened R&D engine and collaborations with leading academic institutions. The Company expects the proposed transaction to be accretive and to enhance its asset base, revenue, margins, and cash flow over time, including through: Significant asset base expansion: Doc Pharma brings an approximately $24 million asset base, expected to meaningfully expand Cosmos Health’s balance sheet following completion of the proposed acquisition. Revenue contribution: Doc Pharma generated approximately $6.7 million in three-year average annual revenue, expected to support Cosmos Health’s growth profile. Meaningful gross profit contribution: Doc Pharma generated approximately $3.2 million in three-year average annual gross profit, expected to support Cosmos Health’s margin expansion and profitability objectives. Greg Siokas, CEO of Cosmos Health, stated: "This is a defining step in our vision to build a global, diversified, vertically integrated healthcare powerhouse. Doc Pharma brings a state-of-the-art GMP facility, a deep portfolio of advanced and branded generics and OTC pharmaceutical products, and a strong R&D platform. Bringing these capabilities in-house is expected to expand our production capacity, accelerate growth, strengthen margins, enhance profitability, and create lasting value for shareholders. The enlarged platform would be well positioned to advance these objectives.” Doc Pharma is a related-party entity, and the proposed acquisition constitutes a related-party transaction. As such, the proposed transaction will be reviewed by a committee of independent directors, supported by an independent fairness opinion and valuation, as well as a PCAOB audit, and will be subject to shareholder approval. Doc Pharma’s financial figures referenced herein represent average annual figures for the three most recent completed financial years, FY2023, FY2024 and FY2025, and have been converted from euros into U.S. dollars based on the applicable EUR/USD exchange rate as of June 11, 2026. All figures referenced herein are subject to final due diligence. There can be no assurance that the proposed transaction will be completed on the contemplated terms or at all, or that the anticipated benefits will be realized. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, i